Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cells

International Journal of Cancer

Volumn 50, Issue 1, 1992, Pages 64-68

  Marth, Christian ^a   Cronauer, Marcus V ^a   Doppler, Wolfgang ^b   Öfner, Dietmar ^a   Ullrich, Axel ^c   Daxenbichler, Günter ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; OMEGA INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CARCINOMA; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; INTERFERONS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0026569812     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910500114     Document Type: Article

References (26)

1. Purification and characterization of natural human interferonomegal
2. The neu oncogene encodes an epidermal growth‐factor‐receptor‐related protein
3. Over‐expression of HER‐2/neu is associated with poor survival in advanced epithelial ovarian cancer
4. Over‐expression of HER‐2/neu in endometrial cancer is associated with advanced‐stage disease
5. Intraperitoneal recombinant alpha‐2‐interferon for “salvage” immunotherapy in stage‐III epithelial ovarian cancer: a gynecologic oncology group study
6. Effect of human recombinant alpha‐2‐ and gamma‐interferon on the growth of human cell lines from solid tumors and hematologic malignancies
7. Down‐modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
8. 1 arrest
9. Characterization of murine monoclonal antibodies reactive to either the human epidermal‐growth‐factor receptor or HER2/neu gene product
10. The biology of interferon actions
11. Radioimmunoassay for detection of changes in cell‐surface tumor antigen expression induced by interferon
12. Expression of the c‐erb B‐2 protein in normal and transformed cells
13. HER‐2 monoclonal antibody has anti‐proliferative effects in vitro and sensitizes human breast‐tumor cells to tumor necrosis factor
14. Regulation of phosphorylation of the c‐erb B‐2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
15. Intraperitoneal administration of human recombinant interferon‐alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity
16. Effects of biological‐response modifiers on ovarian carcinoma cell lines
17. Die intraperitoneale Instillation von Interferon‐gamma zur Behandlung des refraktären Ovarialkarzinoms
18. Gamma‐interferon reduces expression of the proto‐oncogene c‐erb B‐2 in human ovarian carcinoma cells
19. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
20. Interferons and their actions
21. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene
22. Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer
23. Anti‐receptor antibodies reverse the phenotype of cells transformed by two interacting proto‐oncogene‐encoded receptor proteins
24. A simple ultraviolet spectrophotometric method for the determination of proteins
25. Similarity of protein encoded by the human c‐erb‐B‐2 gene to epidermal‐growth‐factor receptor
26. Tumor necrosis factor reduces c‐myc expression and cooperates with interferon‐gamma in HeLa cells